Bank of America Corp DE decreased its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 55.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 474,858 shares of the company's stock after selling 579,588 shares during the period. Bank of America Corp DE owned approximately 0.07% of Genmab A/S worth $9,910,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC grew its stake in Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after acquiring an additional 939 shares during the period. Lindbrook Capital LLC lifted its holdings in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares in the last quarter. Barclays PLC lifted its holdings in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares in the last quarter. Cromwell Holdings LLC increased its stake in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after purchasing an additional 2,496 shares in the last quarter. Finally, R Squared Ltd acquired a new stake in Genmab A/S during the 4th quarter worth approximately $93,000. Institutional investors own 7.07% of the company's stock.
Analyst Ratings Changes
Several research analysts have recently weighed in on the stock. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Truist Financial reduced their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Finally, William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Genmab A/S currently has a consensus rating of "Moderate Buy" and an average target price of $39.17.
View Our Latest Analysis on GMAB
Genmab A/S Stock Up 2.3%
Shares of NASDAQ GMAB traded up $0.47 during trading hours on Tuesday, hitting $21.28. The company had a trading volume of 1,388,999 shares, compared to its average volume of 1,132,811. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $28.96. The firm's 50 day moving average is $19.78 and its 200-day moving average is $20.65. The stock has a market capitalization of $13.64 billion, a P/E ratio of 12.23, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. The company had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, sell-side analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.
Genmab A/S Company Profile
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
